SAN DIEGO -- (BUSINESS WIRE) -- OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, will present at the LD Micro 4th Invitational, taking place Wednesday, June 4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. This presentation will be the first of its kind to include new positive interim data from the company’s Phase 2 melanoma study, which was recently exhibited at the 2014 ASCO Annual Meeting.
The company’s presentation by Robert Pierce, M.D., OncoSec Chief Medical Officer, is scheduled to begin at 1:00 p.m. PDT and will be available via live webcast. To access the webcast, please use the following link: http://wsw.com/webcast/ldmicro6/oncs.
About LD Micro 4th Invitational
LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The 4th Invitational will feature company presentations and facilitate 1-on-1 meetings between business leaders and investors, as part of LD Micro’s ultimate goal of bringing out the finest ideas in micro-cap and showcasing them to a tight-knit and loyal investor base. For more information, please visit: http://www.ldmicro.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential for a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's clinical programs currently include three Phase 2 trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma respectively (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search). As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications and combination-based approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.